NUP50

Nuclear pore complex protein Nup50 · Q9UKX7 · NUP50 on Sugi Atlas →

0 patent compounds predicted against NUP50, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to NUP50 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD) PHASE3COMPLETED
Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria PHASE2COMPLETED
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers PHASE1/PHASE2RECRUITING
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma PHASE1/PHASE2COMPLETED
Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma PHASE1/PHASE2RECRUITING
Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC) PHASE1/PHASE2COMPLETED
Intrathecal Administration of scAAV9/JeT-GAN for the Treatment of Giant Axonal Neuropathy PHASE1COMPLETED
Role of the Nuclear Pore Component RANBP2 in Inflammatory Responses to Viral Infections nanCOMPLETED
A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma(SELINA) nanRECRUITING
Biomarker for Niemann Pick Type C Disease (BioNPC) nanWITHDRAWN
Establishment of Genomic and Phenotypic Database for Niemann-Pick Disease, Type C nanRECRUITING
Molecular Genetics Study of Nasopharyngeal Carcinoma: Characterization of NCP Susceptibility Gene(s) nanCOMPLETED
Family Study of Head and Neck Cancers in Taiwan nanCOMPLETED
Quantitative Assessment of the Etiologies of Megalencephaly Associated With a Detectable Tumor Risk nanNOT_YET_RECRUITING
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
A Prospective Study of Molecular Detection of Salvageable Early Recurrent Nasopharyngeal Carcinoma After Radiotherapy nanCOMPLETED
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients nanRECRUITING
Identification of Biomarkers Associated With Human Hepatocellular Carcinoma by SELDI nanUNKNOWN
A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes nanCOMPLETED
Biological Signatures Resulting From Occupational Exposure to Complex Mixtures of PAHs nanUNKNOWN
Cell Membrane Potential Regulates Spatial-Specific Mechanoptosis Resistance and Metastasis in Colorectal Cancer Via Mechanotransduction and the PVR/CD96 Axis nanCOMPLETED
Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion nanRECRUITING
Genetic Analysis of Gray Platelet Syndrome nanCOMPLETED
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia nanNOT_YET_RECRUITING
Classification, Functional Stratification and Biomarkers in Ciliopathy (CILLICORIRCM) nanCOMPLETED
EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND) nanRECRUITING
Prenatal Cell-free DNA Screening in Pregnancies With Diverse Genetic Risk Profiles Utilizing Targeted and Whole-exome Sequencing nanNOT_YET_RECRUITING
Evaluation of the Expression and Prognostic Role of Tumor Stem Cell Marker SOX2 in Odontogenic Cysts and Tumors nanCOMPLETED
Treatment of Chronic Lymphocytic Leukemia nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a NUP50 binder may also engage these)

ProteinNameSimilarity
O08587 1.000 O08587 →
Q9JIH2 1.000 Q9JIH2 →
Q7K0D8 0.975 Q7K0D8 →
Q5RB98 0.974 Q5RB98 →
P42567 0.971 P42567 →
P49790 0.971 P49790 →
Q9C829 0.970 Q9C829 →
Q80U93 0.970 Q80U93 →
O15504 0.970 O15504 →
O15117 0.969 O15117 →
Q8CIC2 0.969 Q8CIC2 →
EPS15 Epidermal growth factor receptor substrate 15 0.968 landscape →
P49793 0.968 P49793 →
O60318 0.968 O60318 →
Q5XGN1 0.968 Q5XGN1 →
O60934 0.967 O60934 →
P35658 0.967 P35658 →
P32499 0.967 P32499 →
Q4ADK7 0.967 Q4ADK7 →
Q5ZI22 0.966 Q5ZI22 →
Q5RCV3 0.966 Q5RCV3 →
Q6PFD9 0.966 Q6PFD9 →
Q8HXY9 0.966 Q8HXY9 →
P49791 0.966 P49791 →
Q28E45 0.966 Q28E45 →
Q41583 0.966 Q41583 →
Q3MHS2 0.965 Q3MHS2 →
P98082 0.965 P98082 →
Q8BMI3 0.965 Q8BMI3 →
Q8VY07 0.965 Q8VY07 →